Cytokine
RELEASE

Our assay can help predict the likelihood your candidate has of inducing cytokine release syndrome

What is
CYTOKINE RELEASE
SYNDROME (CRS)?

CRS or cytokine storm, is a broad term to describe uncontrolled cytokine release in response to an administered product, and is a severe and sometimes fatal, side-effect of a number of immunomodulatory monoclonal antibodies and cell therapy treatments.  

Screening at an early stage in the discovery process using our in vitro cytokine release assay will enable you to reduce the immunotoxicity of your candidates by informed rational design.

CRS can result from binding to non-target immune cells or even prolonged binding to the intended target which can elicit an exaggerated effect.

Find other methods of assessing the tumour microenvironment

How do we perform our in vitro
CYTOKINE RELEASE ASSAYS?

PBMCs or whole blood are taken from at least 20 donors and incubated with your therapeutic candidates in a 96 well plate format. Following 2-3 days co-incubation, we evaluate the supernatants for a panel of cytokines in our multiplex format (Luminex). This assay provides you with a wealth of information on multiple cytokines from multiple donors.

In a results-driven manner, our expert immunologists can work with you to develop further immunological assays to interrogate the data arising from the cytokine release assay.

Check out some of the technologies we use for Cytokine Release assays

ACCESS TO
DONORS

Access to a range of donors for whole blood assay, with banks of cryopreserved PBMCs from >70 donors available

ASSAY
BENCHMARKS

Our assays can include benchmark antibodies as controls e.g. Cetuximab or Infliximab (low risk) and Alemtuzumab (high risk)

Meet the team who deliver our Beautiful Bioassays

When is it most appropriate to use a 

CYTOKINE RELEASE ASSAY?

The first-in-man clinical trial of the anti-CD28 super agonist TGN1412 is an extreme example of the potential effects of uncontrolled cytokine release. Cytokine storm has been clinically documented for a number of therapeutic antibodies and is a common adverse event in chimeric antigen receptor (CAR)-T clinical trials.

Our cytokine release assays can help you predict some of the immunotoxicities which may be associated with your candidate. Our expert immunologists will work closely with you to ensure that we offer you the most appropriate assay set up for your therapeutic candidates.

contact us now
to get started


Reason for Enquiry




Antibody Analytics Ltd.

BioCity Scotland, Bo’ness Road,
Newhouse, Lanarkshire, ML1 5UH

Email: info@antibodyanalytics.com
Tel: +44 (0) 1698 534450

Contact Us
close slider

Product of Interest